U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To...
U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To...
U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To Further Appeal
美國最高法院拒絕審查宣佈美國聯合醫療專利無效的裁決；確認liquidia沒有侵犯美國聯合醫療最初維護的三項專利中的任何有效權利的決定現已最終且不能再上訴
- U.S. Supreme Court denied United Therapeutics' petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 ('793 Patent) were invalid
- Decisions that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics are now final and not subject to further appeal
- 美國最高法院否決了美國聯合醫療上訴裁定的請求，認定美國專利10,716,793號('793專利')的所有權利均無效
- 現確認liquidia沒有侵犯美國聯合醫療最初維護的三項專利中的任何有效權利的決定已經最終且不能再上訴
MORRISVILLE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced that the United States Supreme Court has rejected United Therapeutics' (UTHR) petition for a writ of certiorari, which requested permission to appeal prior decisions which found that all claims of U.S. Patent No. 10,716,793 ('793 Patent) are unpatentable due to prior art. As a result, the decision by the Patent Trial and Appeal Board (PTAB) in July 2022, which was affirmed by the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) in December 2023, is now final and not subject to further appeal.
N.C.，2024年10月07日(環球新聞通訊社) -- liquidia公司（納斯達克股票代碼：LQDA）, 一家爲少見心肺疾病患者開發創新療法的生物製藥公司，今天宣佈美國最高法院拒絕了美國聯合醫療(Uthr)的稟議書，請求許可上訴之前裁定美國專利10,716,793號('793專利')的所有權利因先前技術而無法獲得專利。由此，2022年7月專利審試和上訴委員會(PTAB)的決定，於2023年12月得到美國聯邦巡迴法院(Federal Circuit)的確認，現已最終且不受進一步上訴。
譯文內容由第三人軟體翻譯。